Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02566759
Recruitment Status : Terminated (The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.)
First Posted : October 2, 2015
Results First Posted : February 6, 2018
Last Update Posted : June 14, 2021
Sponsor:
Collaborator:
Takeda
Information provided by (Responsible Party):
Neurocrine Biosciences

Brief Summary:
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.

Condition or disease Intervention/treatment Phase
Schizophrenia, Cerebellar Ataxia Drug: TAK-831 Oral Suspension Drug: TAK-831 Placebo Drug: TAK-831 Tablet Phase 1

Detailed Description:

The drug being tested in this study is called TAK-831. TAK-831 is being tested to treat participant who have schizophrenia and cerebellar ataxia. This study will look at the PK, safety and tolerability of TAK-831 in healthy participants. The study will enroll approximately 120 participants. The study will include 4 parts: Part 1 (single-rising dose [SRD]), Part 2 (SRD/multiple-rising dose [MRD]), Part 3 (MRD) and Part 4 (relative bioavailability study). Participants will be randomly assigned (by chance, like flipping a coin) to receive either active drug TAK-831 or placebo which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Part 1, Cohort 1: single dose of TAK-831 100 mg
  • Part 1, Cohort 2: single dose of TAK-831 250 mg
  • Part 1, Cohort 3: single dose of TAK-831 500 mg
  • Part 1, Cohort 4: single dose of TAK-831 30 mg
  • Part 1, Cohort 5: single dose of TAK-831 750 mg
  • Part 1, Cohort 6: single dose of TAK-831 10 mg
  • Part 2, Cohort 1: single dose of TAK-831 30 mg
  • Part 2, Cohort 2: single dose of TAK-831 100 mg
  • Part 2, Cohort 3: single dose of TAK-831 200 mg
  • Part 2, Cohort 4: single dose of TAK-831 400 mg
  • Part 3, Cohort 1: TAK-831 400 mg
  • Part 4: TAK-831 100 mg (Tablet Fasted + Tablet Fed + Suspension Fasted)
  • Part 4: TAK-831 100 mg (Tablet Fed + Tablet Fasted + Suspension Fasted)
  • Part 4: TAK-831 100 mg (Suspension Fasted+ Tablet Fed + Tablet Fasted)

Dosing with TAK-831 will progress into study Part 2, 3 and 4, only after review of all available safety, tolerability, and PK data collected in Cohorts 1 to 6 of the Study Part 1. This single center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately up to 58 days. Participants will be admitted in the clinic for the up to 20 days, and will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study, hence it is was not feasible to collect further CSF samples that were required to meet the exploratory objectives of the study. Part 1, 2 and 4 of the study were completed as planned.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects
Study Start Date : September 23, 2015
Actual Primary Completion Date : June 9, 2016
Actual Study Completion Date : July 12, 2016


Arm Intervention/treatment
Experimental: Part 1, Cohort 1: TAK-831 100 mg
TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 1, Cohort 2: TAK-831 250 mg
TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 1, Cohort 3: TAK-831 500 mg
TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 1, Cohort 4: TAK-831 30 mg
TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 1, Cohort 5: TAK-831 750 mg
TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 1, Cohort 6: TAK-831 10 mg
TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 2, Cohort 1: TAK-831 30 mg
TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 2, Cohort 2: TAK-831 100 mg
TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 2, Cohort 3: TAK-831 200 mg
TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 2, Cohort 4: TAK-831 400 mg
TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 3, Cohort 1: TAK-831 400 mg
TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Placebo
TAK-831 placebo-matching oral suspension.

Experimental: Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)
TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Tablet
TAK-831 tablet.

Experimental: Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)
TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Tablet
TAK-831 tablet.

Experimental: Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)
TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
Drug: TAK-831 Oral Suspension
TAK-831 oral suspension.

Drug: TAK-831 Tablet
TAK-831 tablet.




Primary Outcome Measures :
  1. Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) [ Time Frame: Baseline up to 30 days after the last dose of study drug (Part 1 Day 31, Part 2 Day 46, Part 3 Day 44 and Part 4 Day 43) ]
  2. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose [ Time Frame: Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4 ]
    Clinical laboratory tests included hematology, serum chemistry and urinalysis.

  3. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose [ Time Frame: Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4 ]
    Markedly abnormal criteria for vital signs measurement was assessed. The lower criteria and upper criteria for abnormality are as follow: systolic blood pressure at less than (<) 85 millimeter of mercury (mm Hg) to greater than (>) 180 mm Hg; diastolic blood pressure < 50 mm Hg to >110 mm Hg; pulse rate <50 bpm to >120 bpm; Temperature <35.6 degree Celsius to >37.7 degree Celsius.

  4. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose [ Time Frame: Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4 ]
    Markedly abnormal criteria for ECG was assessed. The lower cut-off point criteria and upper cut-off point criteria are as follow: heart rate <50 beats per minute (bpm) to >120 bpm; PR interval less than or equal to (<=) 80 millisecond (msec) to greater than or equal to (>=) 200 msec; QRS interval <=80 msec to >=180 msec; QT interval <=300 msec to >=460 msec; QTcB interval <=300 msec to >=500 msec or >=30 msec change from baseline and >=450 msec; QT interval with Fridericia's correction method (QTcF) interval <=50 msec to >=500 msec or >=30 msec change from baseline and >=450 msec.


Secondary Outcome Measures :
  1. Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose ]
  2. Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831 [ Time Frame: Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose ]
  3. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose; Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose ]
  4. Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose ]
  5. Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose ]
  6. Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831 [ Time Frame: Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Should be capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. Healthy male or female aged between 18 to 55 years- Weighing at least 45 kilogram (kg) and has a body mass index (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m^2).
  4. Male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.
  5. Female participant with no childbearing potential, defined as a participant that has been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or who is post menopausal (defined as continuous amenorrhea of at least 2 years and follicle-stimulating hormone [FSH] greater than [>] 40 international units per liter [IU/L]).

Exclusion Criteria:

  1. Received any investigational compound within 3 months prior to randomization.
  2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress.
  3. Has uncontrolled, clinically significant neurological (including seizure disorders), cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality.
  4. Has a known hypersensitivity to any component of the formulation of TAK-831.
  5. Female participant is of childbearing potential.
  6. Has a positive urine drug result for drugs of abuse (defined as any illicit drug use) at Screening or Check-in.
  7. History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. One unit is equivalent to a half-pint of beer or 1 single measure of spirits or 1 small glass of wine.
  8. Has taken any excluded medication, supplements, or food products during the time periods listed in the excluded medications and dietary products.
  9. Female participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  10. Male participant intending to donate sperm during the course of this study or for 12 weeks after the last dose of study medication.
  11. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma, hypoxemia, hypertension, seizures, or allergic skin rash.
  12. Has a QT interval with Fridericia's correction method (QTcF) >450 millisecond (msec) (males) or >470 msec (females) or PR outside the range of 120 to 220 msec, confirmed with one repeat testing, at the screening visit or check-in (Day -2).
  13. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (that is, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention.
  14. Has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1.
  15. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody/antigen at Screening.
  16. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in. Cotinine test is positive at Screening or Check-in.
  17. Has poor peripheral venous access.
  18. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior to first dose of medication.
  19. Has a Screening or Check-in abnormal (clinically significant) electrocardiogram (ECG). Entry of any participant with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator or designee.
  20. Has a supine blood pressure outside the ranges of 90 to 140 millimeter of mercury (mm Hg) for systolic and 50 to 90 mm Hg for diastolic, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in.
  21. Has a resting heart rate outside the range 40 to 100 bpm confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in.
  22. Has abnormal Screening or check-in laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) >1.5 the upper limits of normal.
  23. Has a risk of suicide according to the Investigator's clinical judgment (example, per The Columbia Suicide Severity Rating Scale [C-SSRS]), or has scored "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior", if this behaviour occurred in the past 2 years.
  24. Has received TAK-831 in a previous clinical study.
  25. Participant is vegan or vegetarian (Part 4 only - food effect).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02566759


Locations
Layout table for location information
United Kingdom
London, United Kingdom
Sponsors and Collaborators
Neurocrine Biosciences
Takeda
Layout table for additonal information
Responsible Party: Neurocrine Biosciences
ClinicalTrials.gov Identifier: NCT02566759    
Other Study ID Numbers: TAK-831-1001
2015-002295-24 ( EudraCT Number )
U1111-1168-6568 ( Registry Identifier: WHO )
15/SC/0412 ( Registry Identifier: NRES )
First Posted: October 2, 2015    Key Record Dates
Results First Posted: February 6, 2018
Last Update Posted: June 14, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Neurocrine Biosciences:
Drug therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Ataxia
Cerebellar Ataxia
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases